Abbott Laboratories (ABT.N) raised its annual profit forecast on Thursday after its second-quarter earnings edged past Wall Street estimates on double-digit growth in sales of its glucose monitors and strong demand for heart devices.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,